MeSH term
Frequency | Condition_Probility | ATP-Binding Cassette Transporters/metabolism | 7 | 14.0 |
Antigen Presentation | 8 | 2.0 |
Antiporters/metabolism | 2 | 33.0 |
Cysteine Endopeptidases/metabolism | 4 | 1.0 |
Down-Regulation | 11 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Histocompatibility Antigens Class I/genetics/*metabolism | 3 | 10.0 |
Humans | 206 | 0.0 |
Immunoglobulins/metabolism | 2 | 1.0 |
*Major Histocompatibility Complex | 17 | 5.0 |
Multienzyme Complexes/metabolism | 3 | 1.0 |
Mutation | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 156 | 0.0 |
ATP-Binding Cassette Transporters/*genetics | 65 | 28.0 |
Adolescent | 21 | 0.0 |
Adult | 32 | 0.0 |
Aged | 11 | 0.0 |
Alleles | 52 | 0.0 |
Child | 20 | 0.0 |
Colombia | 2 | 4.0 |
Cross-Sectional Studies | 2 | 0.0 |
Female | 56 | 0.0 |
Genetic Predisposition to Disease | 14 | 0.0 |
HLA-DQ Antigens/*genetics | 10 | 2.0 |
HLA-DR Antigens/*genetics | 6 | 1.0 |
Histocompatibility Testing | 4 | 0.0 |
Linkage Disequilibrium | 17 | 2.0 |
Major Histocompatibility Complex/genetics | 6 | 10.0 |
Male | 44 | 0.0 |
Middle Aged | 22 | 0.0 |
*Polymorphism, Genetic | 32 | 0.0 |
Sjogren's Syndrome/*genetics/immunology/pathology | 2 | 100.0 |
ATP-Binding Cassette Transporters/*metabolism | 8 | 9.0 |
Adenosine Triphosphate/metabolism | 7 | 1.0 |
Animals | 63 | 0.0 |
Cell Line | 38 | 0.0 |
HLA-B Antigens/metabolism | 2 | 20.0 |
Macromolecular Substances | 6 | 0.0 |
Molecular Chaperones/immunology | 2 | 50.0 |
Rats | 22 | 0.0 |
Transfection | 17 | 0.0 |
Comparative Study | 32 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Genotype | 27 | 0.0 |
Heterozygote | 3 | 0.0 |
Homozygote | 6 | 0.0 |
Japan | 7 | 0.0 |
Major Histocompatibility Complex | 11 | 4.0 |
Polymerase Chain Reaction | 24 | 0.0 |
Base Sequence | 44 | 0.0 |
Case-Control Studies | 8 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 5 | 2.0 |
Finland | 3 | 1.0 |
Gene Frequency | 25 | 0.0 |
Genes, MHC Class II | 5 | 2.0 |
ATP-Binding Cassette Transporters/genetics | 13 | 20.0 |
Exons | 3 | 0.0 |
Introns | 2 | 0.0 |
Japan/epidemiology | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 6 | 0.0 |
*Variation (Genetics) | 5 | 0.0 |
*Genes, MHC Class II | 15 | 4.0 |
Research Support, U.S. Gov't, P.H.S. | 48 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
*Cysteine Endopeptidases | 29 | 61.0 |
HLA-D Antigens/*genetics | 9 | 6.0 |
Proteins/*genetics | 14 | 0.0 |
Immunity/physiology | 2 | 14.0 |
Child, Preschool | 8 | 0.0 |
HLA-B Antigens/*genetics | 3 | 1.0 |
Korea | 3 | 1.0 |
*Multienzyme Complexes | 21 | 28.0 |
Phenotype | 12 | 0.0 |
Polymorphism, Genetic | 26 | 0.0 |
Blotting, Western | 4 | 0.0 |
Cells, Cultured | 11 | 0.0 |
DNA Primers/chemistry | 7 | 0.0 |
Gene Expression | 5 | 0.0 |
Genes, MHC Class I/genetics | 2 | 8.0 |
Histocompatibility Antigens Class I/*metabolism | 11 | 11.0 |
Interferon Type II/pharmacology | 5 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
*Amino Acid Transport Systems | 6 | 50.0 |
*Genes, MHC Class I | 5 | 1.0 |
HLA-DR Antigens/genetics | 21 | 5.0 |
Lymphotoxin/genetics | 2 | 3.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
*Saccharomyces cerevisiae Proteins | 6 | 0.0 |
Tumor Necrosis Factor-alpha/genetics | 3 | 1.0 |
*Antigen Presentation | 19 | 11.0 |
Peptide Fragments/immunology | 2 | 0.0 |
*Repressor Proteins | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 2 | 0.0 |
Chi-Square Distribution | 4 | 0.0 |
HLA-DP Antigens/*genetics | 4 | 4.0 |
Haplotypes/*genetics | 3 | 1.0 |
Major Histocompatibility Complex/*genetics | 14 | 8.0 |
Odds Ratio | 4 | 0.0 |
Amino Acid Sequence | 56 | 0.0 |
Binding Sites | 10 | 0.0 |
Cloning, Molecular | 11 | 0.0 |
Models, Molecular | 2 | 0.0 |
Molecular Sequence Data | 72 | 0.0 |
Protein Conformation | 5 | 0.0 |
Protein Subunits | 4 | 1.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
ATP-Binding Cassette Transporters/genetics/*metabolism | 5 | 8.0 |
Adenosine Triphosphate/*metabolism | 9 | 10.0 |
Flow Cytometry | 11 | 0.0 |
Nucleotides/*metabolism | 3 | 15.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Tumor Cells, Cultured | 17 | 0.0 |
ATP-Binding Cassette Transporters/*genetics/metabolism | 5 | 16.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
Histocompatibility Antigens Class I/metabolism | 7 | 10.0 |
Immunophenotyping | 5 | 0.0 |
Killer Cells, Natural/*immunology | 3 | 0.0 |
Proteins/metabolism | 3 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Mitoxantrone/*pharmacology | 2 | 33.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
English Abstract | 4 | 0.0 |
HLA Antigens/genetics | 2 | 0.0 |
Haplotypes | 14 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Amino Acid Motifs | 3 | 0.0 |
Dimerization | 8 | 0.0 |
Hydrolysis | 3 | 0.0 |
Adenosine Diphosphate/metabolism | 3 | 5.0 |
Microsomes/metabolism | 4 | 3.0 |
Protein Transport | 4 | 0.0 |
Spodoptera | 3 | 1.0 |
ATP-Binding Cassette Transporters/chemistry/*metabolism | 2 | 20.0 |
Hela Cells | 3 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Polymorphism, Single-Stranded Conformational | 5 | 0.0 |
Reference Values | 3 | 0.0 |
Cohort Studies | 3 | 0.0 |
Pedigree | 4 | 0.0 |
Risk Factors | 4 | 0.0 |
Mice | 28 | 0.0 |
beta 2-Microglobulin/*metabolism | 2 | 4.0 |
African Continental Ancestry Group/*genetics | 5 | 1.0 |
Brazil | 2 | 0.0 |
DNA | 3 | 0.0 |
European Continental Ancestry Group/*genetics | 3 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
HLA Antigens/*biosynthesis | 2 | 10.0 |
Histocompatibility Antigens Class I/biosynthesis | 3 | 6.0 |
*Viral Proteins | 3 | 1.0 |
Biological Transport | 22 | 1.0 |
Peptides/metabolism | 3 | 1.0 |
ATP-Binding Cassette Transporters/biosynthesis | 2 | 18.0 |
Aged, 80 and over | 4 | 0.0 |
Disease Progression | 2 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Immunohistochemistry | 6 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Protein Biosynthesis | 5 | 0.0 |
Time Factors | 2 | 0.0 |
beta 2-Microglobulin/biosynthesis | 2 | 16.0 |
Antigen Presentation/*genetics | 6 | 33.0 |
Genes, MHC Class I | 3 | 2.0 |
Gorilla gorilla | 2 | 5.0 |
Hamsters | 5 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Family Health | 2 | 0.0 |
HLA-DP Antigens/genetics | 4 | 8.0 |
Genetic Vectors/chemical synthesis | 2 | 16.0 |
Mice, Inbred C57BL | 7 | 0.0 |
Sequence Deletion | 4 | 0.0 |
ATP-Binding Cassette Transporters/*chemistry/genetics | 2 | 50.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Insects | 3 | 1.0 |
Kinetics | 2 | 0.0 |
*Mutation | 4 | 0.0 |
Precipitin Tests | 6 | 0.0 |
Protein Binding | 15 | 0.0 |
Temperature | 4 | 0.0 |
Disease Susceptibility | 10 | 1.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Microsatellite Repeats | 5 | 0.0 |
Antigen Presentation/*genetics/immunology | 3 | 100.0 |
Graft Rejection/*genetics/immunology | 2 | 22.0 |
*Histocompatibility Antigens Class II | 4 | 6.0 |
Kidney Transplantation/*immunology | 3 | 1.0 |
Acute Disease | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Up-Regulation | 3 | 0.0 |
DNA Primers | 7 | 0.0 |
*Haplotypes | 4 | 1.0 |
Proteins/genetics | 5 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
ATP-Binding Cassette Transporters/chemistry/genetics/*metabolism | 2 | 22.0 |
Peptide Fragments/metabolism | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Antigen Presentation/genetics | 3 | 13.0 |
HLA-DQ Antigens/genetics | 17 | 6.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Peptides/immunology | 2 | 1.0 |
ATP-Binding Cassette Transporters/*chemistry | 3 | 100.0 |
COS Cells | 2 | 0.0 |
Photochemistry | 3 | 5.0 |
Structure-Activity Relationship | 6 | 0.0 |
Viral Matrix Proteins/genetics | 2 | 9.0 |
Endoplasmic Reticulum/immunology/metabolism | 3 | 60.0 |
Peptides/*metabolism | 2 | 1.0 |
Cysteine Endopeptidases/genetics | 2 | 16.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
Histocompatibility Antigens Class I/genetics | 2 | 2.0 |
Proteasome Endopeptidase Complex | 6 | 1.0 |
*Linkage Disequilibrium | 3 | 1.0 |
*Chromosomes, Human, Pair 6 | 3 | 1.0 |
Histocompatibility Antigens Class I/*biosynthesis | 2 | 5.0 |
beta 2-Microglobulin/genetics | 2 | 9.0 |
Haplotypes/genetics | 5 | 0.0 |
Models, Genetic | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Species Specificity | 7 | 0.0 |
Substrate Specificity | 5 | 0.0 |
ATP-Binding Cassette Transporters/*genetics/*immunology | 3 | 75.0 |
Polymorphism, Genetic/*immunology | 3 | 9.0 |
ATP-Binding Cassette Transporters/chemistry/*genetics | 3 | 15.0 |
Multigene Family/*immunology | 2 | 8.0 |
Phylogeny | 2 | 0.0 |
*Zebrafish Proteins | 2 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 9 | 0.0 |
Regression Analysis | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Genes, MHC Class II/*genetics | 6 | 8.0 |
HLA Antigens/*genetics | 4 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Antigen Presentation/*immunology | 3 | 3.0 |
Calcium-Binding Proteins/metabolism | 3 | 3.0 |
Calreticulin | 2 | 8.0 |
Glycosylation | 4 | 0.0 |
Protein Binding/immunology | 2 | 1.0 |
Ribonucleoproteins/metabolism | 2 | 6.0 |
Histocompatibility Antigens Class I/*genetics/immunology | 2 | 7.0 |
ATP-Binding Cassette Transporters/*genetics/immunology | 6 | 60.0 |
Histocompatibility Antigens Class I/*immunology | 4 | 3.0 |
Biological Transport/immunology | 3 | 11.0 |
Protein Processing, Post-Translational/immunology | 2 | 16.0 |
Blotting, Northern | 3 | 0.0 |
Spleen/metabolism | 2 | 1.0 |
*Xenopus Proteins | 2 | 0.0 |
HLA-B27 Antigen/*genetics | 2 | 10.0 |
RNA, Messenger/analysis | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 5 | 1.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Pregnancy | 3 | 0.0 |
ATP-Binding Cassette Transporters/*biosynthesis | 2 | 33.0 |
*Alleles | 11 | 0.0 |
*Antiporters | 2 | 8.0 |
Carrier Proteins/*genetics | 18 | 1.0 |
*Immunoglobulins | 2 | 7.0 |
Genetic Markers | 3 | 0.0 |
Endoplasmic Reticulum/*metabolism | 2 | 1.0 |
Genes, MHC Class I/*genetics | 2 | 2.0 |
Major Histocompatibility Complex/immunology | 2 | 4.0 |
*Linkage (Genetics) | 2 | 0.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
ATP-Binding Cassette Transporters/*immunology | 2 | 50.0 |
Antibody Specificity | 2 | 0.0 |
HLA Antigens/metabolism | 3 | 9.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Antigen Presentation/*physiology | 3 | 27.0 |
Epitopes/immunology | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
T-Lymphocytes/metabolism | 2 | 0.0 |
Autoantibodies/analysis | 2 | 1.0 |
*ATP-Binding Cassette Transporters | 31 | 26.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Endoplasmic Reticulum/metabolism | 9 | 3.0 |
Recombinant Proteins | 4 | 0.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Histocompatibility Antigens Class I/genetics/immunology | 2 | 13.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Histocompatibility Antigens Class II/*genetics | 18 | 9.0 |
Variation (Genetics) | 3 | 0.0 |
DNA/analysis | 3 | 0.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 5 | 8.0 |
ATP-Binding Cassette Transporters/*biosynthesis/genetics | 2 | 11.0 |
Histocompatibility Antigens Class I/analysis/physiology | 2 | 66.0 |
Psoriasis/*genetics | 3 | 4.0 |
Cell Line, Transformed | 3 | 0.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics | 2 | 9.0 |
Sequence Analysis | 2 | 0.0 |
*Exoribonucleases | 2 | 66.0 |
Measles Vaccine/*immunology | 2 | 40.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Lupus Erythematosus, Systemic/*genetics | 2 | 3.0 |
Polymorphism, Genetic/immunology | 3 | 12.0 |
ATP-Binding Cassette Transporters/biosynthesis/*genetics | 2 | 18.0 |
Epithelium/metabolism | 2 | 0.0 |
Genes, MHC Class II/*immunology | 2 | 10.0 |
HLA-D Antigens/genetics | 4 | 10.0 |
Linkage Disequilibrium/*immunology | 2 | 50.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Protein Transport/*physiology | 2 | 4.0 |
Baculoviridae/genetics | 2 | 1.0 |
Peptides/chemistry/metabolism | 3 | 6.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Major Histocompatibility Complex/*immunology | 2 | 5.0 |
HLA-DR4 Antigen/*genetics | 3 | 10.0 |
Histocompatibility Antigens Class II/genetics | 3 | 2.0 |
Disease Susceptibility/immunology | 2 | 2.0 |
Recombination, Genetic | 2 | 0.0 |
Random Allocation | 2 | 0.0 |
Multiple Sclerosis/*genetics | 5 | 6.0 |
Genes, MHC Class II/genetics | 2 | 7.0 |
Vaccinia virus/genetics | 2 | 2.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Ethnic Groups | 3 | 1.0 |
Antigen-Presenting Cells/*immunology | 3 | 2.0 |
Mice, Inbred C3H | 2 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
H-2 Antigens/immunology | 2 | 9.0 |
In Vitro | 2 | 0.0 |
Infant | 4 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Histocompatibility Antigens Class II/metabolism | 2 | 2.0 |
Affinity Labels | 2 | 3.0 |
Carrier Proteins/*metabolism | 4 | 0.0 |
DNA/genetics | 2 | 0.0 |
Histocompatibility Antigens Class II/*metabolism | 4 | 7.0 |
Arthritis, Rheumatoid/*genetics/immunology | 2 | 4.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Carrier Proteins/genetics/*physiology | 2 | 2.0 |
Histocompatibility Antigens Class II/genetics/*physiology | 2 | 100.0 |
Peptides/*immunology/metabolism | 2 | 16.0 |
Celiac Disease/*genetics | 2 | 7.0 |
Peptides/chemistry | 2 | 0.0 |
Zimbabwe | 2 | 7.0 |
